Previous 10 | Next 10 |
IsoPlexis to Present IsoLight® Single-Cell Proteomics Data at ASH 2021 Conference PR Newswire BRANFORD, Conn. , Dec. 8, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single cell proteomics, today announced that new data gen...
The shares of the Life sciences company, IsoPlexis Corporation (ISO -12.8%) have continued the losing streak for the fifth consecutive session to reach the lowest level since its IPO about two months ago. IsoPlexis (NASDAQ:ISO) shares crashed when the company made its public debut in early Oc...
IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies Leadership from Luminex, Thermo Fisher Scientific, and Perkin Elmer join the IsoPlexis team PR Newswire BRANFORD, Conn. , Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NAS...
IsoPlexis to Participate in the Evercore ISI HealthCONx Conference PR Newswire BRANFORD, Conn. , Nov. 24, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today announced the company will be participa...
IsoPlexis' Expanded Cell Therapy Offerings Demonstrated in Nature Medicine Publications Company broadens range of workflows in "Functional Cell Library" to accelerate cell therapy manufacturing and clinical studies PR Newswire BRANFORD, Conn. , Nov. 18, 2021 ...
IsoPlexis Bolsters Its Global Operational and Product Support Leadership Company appoints industry veterans from Qiagen and PerkinElmer PR Newswire BRANFORD, Conn. , Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-c...
Recently IPO’ed life sciences company, IsoPlexis Corporation (ISO +4.4%) is trading higher after the company reported Q3 financials for 2021. While revenue climbed ~28% YoY to $4.2M beating the Street forecasts, net loss more than quadrupled to $20.2M as sales and marketing expens...
IsoPlexis (NASDAQ:ISO): Q3 GAAP EPS of -$10.66 misses by $9.79. Revenue of $4.19M (+27.7% Y/Y) beats by $0.39M. Press Release For further details see: IsoPlexis EPS misses by $9.79, beats on revenue
IsoPlexis Reports Third Quarter 2021 Financial Results Year-to-date 2021 revenue increased 68% over prior year period PR Newswire BRANFORD, Conn. , Nov. 10, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell p...
IsoPlexis to Present Data at SITC 2021 Connecting Genetic Drivers to Functional Proteomics Company to introduce new immunology applications for Duomic®, a novel simultaneous single-cell transcriptomics and functional proteomics platform, and clinical single-cell proteomics ...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) IsoEnergy Limited (TSX-V:ISO) president Tim Gabruch, delves into the strategic merger with Consolidated Uranium, marking a pivotal transformation into a global uranium industry contender. In an interview with Proactive's Angela Harmantas at PDAC 2024, Gabruch noted that t...
SASKATOON, Saskatchewan, Jan. 19, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an amended agreement with Eight Capital, as co-lead underwriter and joint bookrunner o...
SASKATOON, Saskatchewan, Jan. 18, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an agreement with Eight Capital to act as co-lead underwriter and joint bookrunner on ...